Lamivudine for chronic hepatitis B

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 173-180

  Leung, Nancy ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epivir; Hepatitis B; Lamivudine; Lamivudine resistant mutants

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; FAMCICLOVIR; FAMIVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MUTATIONAL ANALYSIS; NEPHROTOXICITY; PASSIVE IMMUNIZATION; PATIENT SELECTION; PRACTICE GUIDELINE; RECURRENT INFECTION; REVIEW; UNITED STATES; VERTICAL TRANSMISSION; VIRUS MUTANT;

EID: 2942560801     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.173     Document Type: Review

References (51)

1. Lai CL, Chien RN, Leung NWY et al. A 1 year trial of lamivudine for chronic hepatitis Br. N. Engl. J. Med. 339, 61-68 (1998).
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256-1263 (1999).
3. Tassopoulos NC, Volepes R, Pastores G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Mutant Study Group. Hepatology 29(3), 889-896 (1999).
4. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and interferon-α combination treatment of patients with chronic hepatitis B infection, a randomized trial. Gut 46, 562-568 (2000).
5. Jarvis B, Faulds D. Lamivudine - a review of its therapeutic potential in chronic hepatitis B. Drugs 58(1), 101-104 (1999).
6. Liaw YF, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172-180 (2000).
7. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51(4), 597-599 (2002).
8. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30(3), 770-774 (1999).
9. Perillo RP, Lai CL, Liaw YF et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36(10), 186-194 (2002).
10. Guan R, Lai CL, Liaw YF et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis. Gastroenterol. Hepatol. 16(Suppl.) 187 (2001) (Abstract A60).
11. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B, 2000 - summary of a workshop. Gastroenterology 120, 1828-1853 (2001).
12. Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asia-Pacific consensus statement on the management of chronic hepatitis B, an update. J. Gastroenterol. Hepatol. 18(3), 239-245 (2003).
13. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. Geneva, Switzerland, 14-16 September 2002. J. Heptol. 39(Suppl. 1) S1-S235 (2003).
14. Allen MI, Gauthier J, Des Lauriers M et al. Two sensitive PCR-based methods for the detection of virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 37, 3338-3347 (1999).
15. Stuyver LJ, Lorcarnini SA, Lok A et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33(3), 751-757 (2001).
16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30(2), 567-572 (1999).
17. Lok A, Lai CL, Leung N et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6), 1417-1422 (2003).
18. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical corelates of YMDD variants during lamivudine therapy for patients with chronic hepatitis. Br. Clin. Infect. Dis. 36(6), 687-689 (2003).
19. Wong VW, Chan HLY, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutant. Aliment. Pharmacol. Ther. 19(3), 323-329 (2004).
20. Perrillo R, Hann HWL, Mutimer D et al. Adefovir dipivoxil added to maintenance lamivudine in chronic hepatitis B with YMDD mutants HBV and a reduced response to lamivudine. Gastroenterology 126(1), 81-90 (2004)
21. Leung NWY, Lai CL, Chang TT et al. and the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances heaptitis e antigen seroconversion rates, results after 3 years of therapy. Hepatology 33(6), 1527-1532 (2001).
22. Dienstag JL, Goldin RD, Heathecoate EJ et al. Histological outcome during long term lamividine therapy. Gastroenterology 124(1), 105-117 (2003).
23. Leung NWY, Lai CL, Guan R, Liaw Y-F. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 34(4), 348A (2001) (Abstract 706).
24. Leung NW, Liaw Y-F, Chang T-T et al. Durable HBeAg response in Chinese patients treated with lamivudine. Hepatology 34(4), 348A (2001) (Abstract 705).
25. Dienstag JL, Cianciara J, Karayalcin S et al. Durabililty of serology after lamivudine treatment of chronic hepatitis B. Hepatology 37(4), 748-755 (2003).
26. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32, 803-806 (2000).
27. Ryu SH, Chung YH, Choi MH et al. Long term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss, a prospective study. J. Hepatol. 39(4), 614-619 (2003).
28. Van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B, relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52(3), 420-424 (2003).
29. Chien R-N, Yeh C-T, Tsai S-L, Chu C-M, Liaw Y-F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 38, 1267-1273 (2003).
30. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. Hepatology 38(3), 322-327 (2003).
31. Chan HL, Tsang SW, Hui Y, Leung NW, Chan FY, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J. Viral. Hepat. 9(6), 424-428 (2002).
32. Villeneuve J-P, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31, 207-210 (2000).
33. Liaw YF, Sung JY, Chow WC, Shue K, Keene O, Farrell G. Effect of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B. A prospective double-blind placebo-controlled clinical trial. Hepatology 38(4) (Suppl. 1), 262A (2003).
34. Perillo RP, Wright T, Rakela J. et al. and the Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-432 (2001).
35. Nery JR. Nery-Avila C, Reddy KR et al. Use of grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis IgG immunoglobulin and lamivudine. Tranplantation 75(8), 1179-1186 (2003).
36. Fabrega E, Garcia-Suarez C, Guerra A et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl. 9(9), 916-920 (2003).
37. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 116(1), 166-169 (2002).
38. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 115(1), 58-62 (2001).
39. Jonas MM, Kelly DA, Mzerski J et al. and the International Paediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N. Engl. J. Med. 346(22), 1706-1713.
40. Zucker SD. Commentary. All kidding aside with the use of lamivudine in children with chronic hepatitis B. Gastroenterology 123[5], 1741-1743) (2002).
41. Jonas MM, Kelly DA, Mizerski J. et al. and the International Paediatric Lamivudine Investigator Group. Extended lamivudine therapy in children with chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 710A (2002).
42. Hartman C, Berkowitz D, Shouval DS et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediat. Infect. Dis. J. 22(3), 224-229 (2003).
43. Leung NWY. Lamivudine therapy for children with chronic hepatitis B. J. Hepatol. 38, 698-701 (2003).
44. van Nunen AB, de Man R, Heijtink RA, Niesters HGM, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B virus patients. J. Hepatol. 32(6), 1040-1041 (2000) (Letter).
45. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudien therapy. Lancet 359, 1488-1489 (2002).
46. van Zonneveld M, van Nunen AB, Niesters HGM, de Man R, Schalm SW, Janssen HLA. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J. Viral. Hepatol. 10, 294-297 (2003).
47. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission, a clinical study. World J. Gastroenterol. 9(7), 1501-1503 (2003).
48. Lai CL, Leung NWY, Teo EK et al. Results of a 1-year international Phase IIB comparative trial of telbivudine, lamivudine and the combination, in patients with chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 262A (2003).
49. Schiff ER, Dienstag JL, Karayalcin S et al. and the International Lamivudine Investigator Group. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 38(6), 818-826 (2003).
50. Sung JJY, Chan HLY, Hui AY et al. Combination of pegylated interferon and lamivudine is superior to lamivudine monotherapy in the treatment of chronic hepatitis B - a randomized trial. J. Hepatol. 38(Suppl. 2), 33 (2003).
51. 2a (40 KD) (Pegasis®) alone or in combination with lamivudine vs. lamivudine in 546 patients with HBeAg-negative/anti-HBe positive chronic hepatitis B. Hepatology 38(4) (Suppl. 1), 724A (2003).